Author

T. Kindler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

H. Glimm· 2 shared A. Banito· 1 shared A. Carazzato· 1 shared A. M. Dobberkau· 1 shared A. Mizi· 1 shared A. Nilsson· 1 shared A. Papantonis· 1 shared A. Stenzinger· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Glimm

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions

J. Schopf, S. Uhrig, C. E. Heilig, K.-S. Lee, T. Walther, A. Carazzato, A. M. Dobberkau, D. Weichenhan, C. Plass, M. Hartmann, G. D. Diwan, Z. Carrero, C. R. Ball, T. Hohl, T. Kindler, , C. Scholl

This study characterizes soft-tissue sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions through multi-omics analyses and functional studies, identifying therapeutic targets and mechanisms of disease.

bioRxiv · Feb 19, 2023Cancer Biology

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca

This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

C. Messerschmidt, B. Obermayer, K. Klinghammer, S. Ochsenreither, D. Treue, A. Stenzinger, H. Glimm, S. Fröhling, T. Kindler, C. H. Brandts, K. Schulze-Osthoff, W. Weichert, I. Tinhofer, F. Klauschen, U. Keilholz, , D. T. Rieke

The paper identifies an APOBEC-enriched subgroup of HPV-negative HNSCC with distinct immunogenic features linked to immune evasion and potential response to immunotherapy.

bioRxiv · Mar 28, 2019Cancer Biology

Spatial chromosome folding and active transcription drive DNA fragility and formation of oncogenic MLL translocations

H. J. Gothe, B. A. M. Bouwman, E. G. Gusmao, R. Piccinno, S. Sayols, O. Drechsel, G. Petrosino, V. Minneker, N. Josipovic, A. Mizi, C. F. Nielsen, E.-M. Wagner, S. Takeda, H. Sasanuma, D. F. Hudson, , V. Roukos

The paper shows that transcription and spatial chromosome folding increase DNA fragility, leading to oncogenic translocations in leukemia.

bioRxiv · Dec 3, 2018Cell Biology